EBS

#3046
Emergent Biosolutions, Inc.
8.0600 USD
+0.37%
Sektör: Sağlık Hizmetleri
Baz: USD
Kar Para Birimi: USD
Günlük Aralık
8.0301
8.0750
Yıllık Aralık
7.7400
11.4600
Günlük Değişim
+0.37%
Aylık Değişim
+0.25%
6 Aylık Değişim
-24.81%
Yıllık Değişim
-24.81%
Önceki Kapanış
8.0300
Açılış
8.0575
Düşük
8.0301
High
8.0750
Hacim
159
Tam grafiği aç

Financials

Genel Bakış Tablolar İstatistikler
Çeyreklik Yıllık
  • Market Capitalization 417.2731 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr.Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry İlaç Üreticileri - Özel ve Eşdeğer
Toplam gelir
Net kar
Temel hisse başına kazanç (Temel EPS)
Toplam borç
Serbest nakit akışı
Nakit ve eşdeğerleri
Fiyat/kazanç oranı
13.29
Fiyat/satışlar oranı
0.94

Emergent BioSolutions Inc

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Haberler